Cargando…

Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma

OBJECTIVE: To investigate the safety and efficacy of radiofrequency ablation combined with transarterial chemoembolization in patients with specially located small hepatocellular carcinoma. MATERIALS AND METHODS: Between March 2014 and March 2017, a total of 26 patients with 26 lesions (10 perivascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Wei, Yang, Min-Jie, Xu, Jiang, Yan, Zhi-Ping, Liu, Rong, Qu, Xu-Dong, Wang, Jian-Hua, Qian, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071156/
https://www.ncbi.nlm.nih.gov/pubmed/30045673
http://dx.doi.org/10.1177/1533033818788529
_version_ 1783343820227739648
author Yuan, Wei
Yang, Min-Jie
Xu, Jiang
Yan, Zhi-Ping
Liu, Rong
Qu, Xu-Dong
Wang, Jian-Hua
Qian, Sheng
author_facet Yuan, Wei
Yang, Min-Jie
Xu, Jiang
Yan, Zhi-Ping
Liu, Rong
Qu, Xu-Dong
Wang, Jian-Hua
Qian, Sheng
author_sort Yuan, Wei
collection PubMed
description OBJECTIVE: To investigate the safety and efficacy of radiofrequency ablation combined with transarterial chemoembolization in patients with specially located small hepatocellular carcinoma. MATERIALS AND METHODS: Between March 2014 and March 2017, a total of 26 patients with 26 lesions (10 perivascular, 6 subdiaphragmatic, 5 subcapsular, 5 perivascular, and subdiaphragmatic location; mean diameter 2.12 (0.62) cm), who received radiofrequency ablation–transarterial chemoembolization treatment, were retrospectively analyzed. Local tumor response was assessed by computed tomography/magnetic resonance imaging 1 month after the procedure. Tumor-free survival was also assessed according to the modified Response Evaluation Criteria in Solid Tumors. Complications were evaluated according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 4.0). RESULTS: Complete response was achieved in all patients 1 month after the procedure. During a median follow-up duration of 16.76 months (95% confidence interval: 7.78-25.73 months), local tumor recurrence occurred in 2 patients and new intrahepatic lesions developed in 7 patients. The 1-, 2-, and 3-year cumulative local tumor progression rates were 3.84%, 7.69%, and 7.69%, respectively. The median tumor-free survival duration was 21.96 months (95% confidence interval: 17.58-26.34 months). The 1-, 2-, and 3-year tumor-free survival rates were 67.4%, 46.1%, and 39.3%, respectively. CONCLUSION: The radiofrequency ablation–transarterial chemoembolization combination therapy appears to be safe and effective and might be a treatment option for specially located small hepatocellular carcinoma lesions that have a risk of incomplete ablation or major complications.
format Online
Article
Text
id pubmed-6071156
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60711562018-08-06 Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma Yuan, Wei Yang, Min-Jie Xu, Jiang Yan, Zhi-Ping Liu, Rong Qu, Xu-Dong Wang, Jian-Hua Qian, Sheng Technol Cancer Res Treat Original Article OBJECTIVE: To investigate the safety and efficacy of radiofrequency ablation combined with transarterial chemoembolization in patients with specially located small hepatocellular carcinoma. MATERIALS AND METHODS: Between March 2014 and March 2017, a total of 26 patients with 26 lesions (10 perivascular, 6 subdiaphragmatic, 5 subcapsular, 5 perivascular, and subdiaphragmatic location; mean diameter 2.12 (0.62) cm), who received radiofrequency ablation–transarterial chemoembolization treatment, were retrospectively analyzed. Local tumor response was assessed by computed tomography/magnetic resonance imaging 1 month after the procedure. Tumor-free survival was also assessed according to the modified Response Evaluation Criteria in Solid Tumors. Complications were evaluated according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 4.0). RESULTS: Complete response was achieved in all patients 1 month after the procedure. During a median follow-up duration of 16.76 months (95% confidence interval: 7.78-25.73 months), local tumor recurrence occurred in 2 patients and new intrahepatic lesions developed in 7 patients. The 1-, 2-, and 3-year cumulative local tumor progression rates were 3.84%, 7.69%, and 7.69%, respectively. The median tumor-free survival duration was 21.96 months (95% confidence interval: 17.58-26.34 months). The 1-, 2-, and 3-year tumor-free survival rates were 67.4%, 46.1%, and 39.3%, respectively. CONCLUSION: The radiofrequency ablation–transarterial chemoembolization combination therapy appears to be safe and effective and might be a treatment option for specially located small hepatocellular carcinoma lesions that have a risk of incomplete ablation or major complications. SAGE Publications 2018-07-25 /pmc/articles/PMC6071156/ /pubmed/30045673 http://dx.doi.org/10.1177/1533033818788529 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Yuan, Wei
Yang, Min-Jie
Xu, Jiang
Yan, Zhi-Ping
Liu, Rong
Qu, Xu-Dong
Wang, Jian-Hua
Qian, Sheng
Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma
title Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma
title_full Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma
title_fullStr Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma
title_full_unstemmed Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma
title_short Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma
title_sort radiofrequency ablation combined with transarterial chemoembolization for specially located small hepatocellular carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071156/
https://www.ncbi.nlm.nih.gov/pubmed/30045673
http://dx.doi.org/10.1177/1533033818788529
work_keys_str_mv AT yuanwei radiofrequencyablationcombinedwithtransarterialchemoembolizationforspeciallylocatedsmallhepatocellularcarcinoma
AT yangminjie radiofrequencyablationcombinedwithtransarterialchemoembolizationforspeciallylocatedsmallhepatocellularcarcinoma
AT xujiang radiofrequencyablationcombinedwithtransarterialchemoembolizationforspeciallylocatedsmallhepatocellularcarcinoma
AT yanzhiping radiofrequencyablationcombinedwithtransarterialchemoembolizationforspeciallylocatedsmallhepatocellularcarcinoma
AT liurong radiofrequencyablationcombinedwithtransarterialchemoembolizationforspeciallylocatedsmallhepatocellularcarcinoma
AT quxudong radiofrequencyablationcombinedwithtransarterialchemoembolizationforspeciallylocatedsmallhepatocellularcarcinoma
AT wangjianhua radiofrequencyablationcombinedwithtransarterialchemoembolizationforspeciallylocatedsmallhepatocellularcarcinoma
AT qiansheng radiofrequencyablationcombinedwithtransarterialchemoembolizationforspeciallylocatedsmallhepatocellularcarcinoma